Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine

Summary

The study is being conducted to explore the safety and effectiveness of a new chemical entity, BGC20-1531, in subjects with a history of migraine. In this study subjects will treat a total of three migraine attacks with two different doses of BGC20-1531 and placebo, with at least one week wash out period between doses.

Timeline

Start

—

Primary completion

—

Completion

—

Outcome

Outcome not reported

Stopped (Enrollment): “No patients enrolled. Delay due to optimisation of drug product formulation.”

Drugs

Indications